Meghan McCord

Title: Meghan McCord: Innovator in Neuroprotection

Introduction

Meghan McCord is a prominent inventor based in Pittsburgh, PA (US). She has made significant contributions to the field of neuroprotection through her innovative research and patented inventions. Her work focuses on developing peptides that can potentially save neuronal cells from death, which is crucial in various neurological conditions.

Latest Patents

Meghan McCord holds a patent for "Kv2.1 channel-derived peptides and methods of use." This patent describes peptides capable of interfering with the Kv2.1-mediated apoptotic Kcurrent surge that leads to neuronal cell death. The disclosed peptides are derived from the C-terminal region of Kv2.1, which mediates binding to the SNARE protein syntaxin. Disruption of Kv2.1 binding to syntaxin inhibits the apoptotic Kcurrent surge that leads to neuronal cell death. The present disclosure provides methods of inhibiting binding of Kv2.1 to syntaxin in a cell, either in vitro or in vivo. This innovation has potential applications for neuroprotection following cerebral ischemia, stroke, traumatic brain injury, or during the course of neurodegenerative diseases.

Career Highlights

Meghan McCord is affiliated with the University of Pittsburgh, where she conducts her research and develops her inventions. Her work has garnered attention for its potential impact on treating neurological disorders and improving patient outcomes.

Collaborations

Meghan collaborates with Elias Aizenman, a fellow researcher, to further explore the implications of her patented peptides in neuroprotection.

Conclusion

Meghan McCord's innovative work in developing Kv2.1 channel-derived peptides represents a significant advancement in neuroprotection. Her contributions have the potential to change the landscape of treatment for various neurological conditions.